Tizanidine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Tizanidine: Repurposing Potential for Migraine Disorder
One-Sentence Summary
The evidence pack does not include a confirmed original indication for Tizanidine (DrugBank DB00697), as it is not currently marketed in the UK and no marketing authorisation records are available. The TxGNN model predicts it may be effective for Migraine Disorder, with 2 clinical trials and 18 publications currently supporting this direction, including one Phase 3 RCT specifically testing tizanidine for migraine prevention.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack — tizanidine is not currently marketed in the UK and no licence records are available |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal mechanism-of-action data from DrugBank is currently unavailable for this drug (flagged as a High-severity data gap, remediation pending via the DrugBank API). However, the evidence pack’s mechanistic assessment describes tizanidine as a centrally acting α2-adrenergic receptor agonist, in the same pharmacological class as clonidine. It is understood to inhibit noradrenaline release from the locus coeruleus and to reduce excitatory neurotransmitter release from spinal interneurons.
This pathway overlaps mechanistically with the central sensitisation and trigeminovascular system activation processes implicated in migraine pathophysiology, providing a theoretical rationale for a preventive role in migraine attacks. Tizanidine’s established muscle-relaxant properties may also be relevant to migraine subtypes with a significant myofascial/tension component.
This mechanistic plausibility is reinforced by a body of older literature (dating back to the 1990s–2000s) exploring tizanidine in chronic daily headache and tension-type headache, together with a currently recruiting Phase 3 RCT (NCT05484349) designed specifically to test tizanidine for migraine prevention in adults — the most direct evidence source identified to date.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05484349 | Phase 3 | Recruiting | 189 | Multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of oral tizanidine hydrochloride for preventing migraine attacks in adults (18–65 years) with episodic migraine (with or without aura). Direct, high-relevance evidence for this indication. |
| NCT02403687 | N/A | Completed | 300 | 24-week observational prospective study on the efficacy of topical NSAIDs for pain relief; broad analgesic comparator study, only indirectly relevant to tizanidine’s migraine use. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12167135 | 2002 | RCT (double-blind, placebo-controlled) | Headache | Multicentre outcome study assessing tizanidine hydrochloride versus placebo as adjunctive prophylactic therapy for chronic daily headache (chronic migraine, migrainous headache, tension-type headache). |
| 31365643 | 2019 | Guideline/Consensus | Arq Neuropsiquiatr | Brazilian Headache Society consensus on chronic migraine treatment; tizanidine included among recommended prophylactic options. |
| 11318882 | 2001 | Open-label trial | Headache | Open-label dose-titration study assessing efficacy and tolerability of tizanidine hydrochloride tablets for prophylaxis of chronic daily headache. |
| 20464578 | 2010 | Review | Neurol Sci | Critical review of published double-blind, placebo-controlled trials on pharmacological prophylaxis of chronic migraine. |
| 23293866 | 2013 | Review | Headache | Rational approach to chronic migraine management; lists tizanidine among agents with evidence for prophylaxis alongside topiramate and onabotulinumtoxinA. |
| 15115635 | 2004 | Review | Curr Pain Headache Rep | Review of emerging migraine prophylaxis options, including tizanidine data alongside topiramate, levetiracetam and other agents. |
| 12696998 | 2003 | Review | CNS Drugs | Reviews agents affecting muscle spasm/tone (baclofen, tizanidine, botulinum toxin A) as potential preventative treatments for migraine and tension-type headache. |
| 17115988 | 2006 | Review | Headache | Review of prophylactic treatment for chronic daily headache; tizanidine discussed among agents with trial evidence. |
| 21770931 | 2011 | Review | Headache | Discusses implications of clinical trials on medication overuse and chronic migraine prophylaxis, including tizanidine. |
| 40983294 | 2025 | Preclinical | J Control Release | Describes supramolecular co-crystal self-assembly of tizanidine with meloxicam, showing synergistic anti-migraine efficacy in preclinical models. |
UK Market Information
No UK marketing authorisations were identified for tizanidine in this evidence pack (total_licenses = 0). The drug is currently recorded as not marketed in the UK, so no product name, dosage form or approved indication text is available to report.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Detailed product-label warnings and contraindications for tizanidine were not available in this evidence pack (flagged as a Blocking-severity data gap), so a formal S1 safety evaluation cannot yet proceed. No drug–drug interaction records were returned by the current query.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A plausible mechanistic rationale (α2-adrenergic agonism, class effect overlap with established headache-prophylaxis literature) is supported by one ongoing Phase 3 RCT (NCT05484349) directly testing tizanidine for migraine prevention, plus a body of older exploratory studies in chronic daily headache and tension-type headache. Evidence level is L2 — sufficient to justify further investment, but not yet sufficient for unconditional progression, particularly given outstanding safety data gaps.
To proceed, the following is needed:
- Product-label warnings and contraindications (currently a Blocking data gap) — required before a formal S1 safety evaluation can be conducted
- Detailed DrugBank mechanism-of-action confirmation (currently a High-severity data gap)
- Monitoring of the completion and results of NCT05484349 (Phase 3, currently recruiting)
- Confirmation of UK regulatory/licensing pathway, given tizanidine is not currently marketed in the UK
- A formal drug–drug interaction review, as the current DDI query returned no results
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.